Thanks Daniel. Under the Melanoma 'family' patents, it says the provisional patents cover "multiple uses of bisantrene in combination with other drugs". Yesterday's news foreshadowed that Zantrene may provide an effective single agent treatment for some Melanomas - would this use case be covered under any of our patents?
General Comments / Chat, page-4137
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |